This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
The authors searched MEDLINE using the term 'hearing tests' and restricted the review to articles written in English.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Ten primary studies were included in the review.
Methods of combining primary studies
A narrative method was used to combine primary studies.
Investigation of differences between primary studies
Results of the review
The results of the review were as follows: prevalence of hearing loss was 0.11% (range: 0.10% -0.59%); sensitivity and specificity of risk screening were 59% (range: 50% -64%) and 95% (range: 91% -99%), respectively; sensitivity and specificity of automated TEOAE were 80% (range: 66% -100%) and 92% (range: 91% -93%), respectively; and sensitivity and specificity of automated ABR were 98% (range: 80% -100%) and 96% (range: 86% -98%), respectively.
Measure of benefits used in the economic analysis
The number of cases identified was used as the measure of health benefits.
Direct costs
Direct costs were not discounted given the short time frame of the study (less than one year). Quantities and unit costs per test were reported separately. Direct costs related to the costs of screening and follow-up testing. The quantity/cost boundary adopted was that of the hospital. Cost data were taken from the published literature and discussions with experts. The price year was not reported.
